The 2022 Tandem Meetings | Advances in off-the-shelf third-party T-cells for the treatment of infectious diseases post-BMT
Michael Keller, MD, Children’s National Health System, Washington, DC, discusses the use of off-the-shelf third-party T-cells for the treatment of infectious diseases following bone marrow transplantation (BMT). A growing number of patients are being treated with these therapies, which are showing promising efficacy. In addition, an increasing number of viruses are being targeted with T-cell virus-specific immunotherapy. This includes norovirus, where a norovirus-specific T-cell therapy is currently being evaluated in the Phase I ATLANTIC trial (NCT04691622) in patients with T-cell deficiencies following BMT or solid organ transplant. Recent studies have also reported the successful use of Epstein-Barr virus-specific T-cells to treat post-transplant lymphoproliferative disorder (PTLD) post solid organ transplant. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
